Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of nivolumab alone and nivolumab plus relatlimab in advanced cutaneous squamous cell carcinoma
2016-002811-16Phase 2Active
- Sponsor
- Paracelsus Medical University
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, relatlimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Paracelsus Medical University. Started Nov 2016; status: active.
02
Drugs
nivolumabrelatlimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2016-002811-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002811-16.